Evidence map›Paper›PMID 42695421›Full record

ReviewInternational journal of oncology2026

MicroRNA regulation of macrophage polarization in lung cancer: Regulatory networks and therapeutic potential (Review).

Zhao Yiming, Li Jie

Abstract readReview
In one paragraph

Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhao YimingClinical Medical College of Beijing University of Chinese Medicine, Beijing 100029, P.R. China.
Li JieClinical Medical College of Beijing University of Chinese Medicine, Beijing 100029, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is among the most prevalent and fatal cancers worldwide, with its progression heavily shaped by the tumor microenvironment (TME). As key immune cell populations within the TME of lung cancer, macrophages are involved in the entire process of tumor initiation and development. Macrophage polarization serves as a critical link between inflammation and tumorigenesis and is broadly divided into classically activated M1 and alternatively activated M2 phenotypes. These phenotypes exert tumor‑suppressive and tumor‑promoting effects, respectively, by secreting distinct cytokine profiles. MicroRNAs (miRNAs/miRs) are a class of endogenous small non‑coding RNAs that play broad roles in the malignant progression of lung cancer by regulating various cellular processes, including proliferation, resistance to apoptosis, and metabolic reprogramming. Emerging evidence suggests that miRNAs such as miR‑335‑5p, miR‑106a‑5p and miR‑99b regulate M1/M2 macrophage polarization by targeting key pathways in lung cancer. Through these regulatory events, miRNAs exert synergistic effects on multiple tumor hallmarks, including proliferation, invasion, migration, apoptosis, angiogenesis, cell cycle progression, stemness maintenance, and epithelial‑mesenchymal transition. Collectively, these events drive lung cancer progression and influence therapeutic efficacy. The present review synthesizes recent discoveries to explore the relationship between macrophage polarization and lung cancer, with a specific focus on miRNA‑mediated regulatory mechanisms in lung cancer therapy. Ultimately, the present review aimed to provide new insight and a reference point to inform future prevention and treatment strategies for lung cancer.

Indexed as

Lung NeoplasmsMacrophagesMicroRNAsAnimalsEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMacrophage ActivationTumor MicroenvironmentMicroRNAslung cancermacrophage polarizationmicroRNAnetworkstherapy

Identifiers

PMID42695421
PMCPMC13553194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.